Finorex 20 mg (Tablet)
Unit Price: ৳ 120.00 (1 x 10: ৳ 1,200.00)
Strip Price: ৳ 1,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | Ziska pharmaceuticals ltd |
| Also available as |
Indications
- Reduce risk of sustained eGFR decline
- Reduce risk of end-stage kidney disease
- Reduce risk of cardiovascular death
- Reduce risk of nonfatal myocardial infarction
- Reduce risk of hospitalization for heart failure
- For adult patients with chronic kidney disease associated with type 2 diabetes (T2D)
Pharmacology
- Nonsteroidal and selective antagonist of the mineralocorticoid receptor (MR)
- Blocks MR mediated sodium reabsorption
- MR overactivation in epithelial and nonepithelial tissues
- High potency and selectivity for the MR
- No relevant affinity for androgen, progesterone, estrogen and glucocorticoid receptors
- Mean systolic blood pressure decrease by 3 mmHg
- Mean diastolic blood pressure decrease by 1-2 mmHg
- Complete absorption after oral administration
- Metabolism resulting in absolute bioavailability of 44%
- Cmax achieved between 0.5 and 1.25 hours after dosing
- Exposure increases proportionally over a dose range of 1.25 to 80 mg
- Steady state achieved after 2 days of dosing
- Metabolized primarily by CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%)
- 80% of the administered dose is excreted in urine
Dosage & Administration
- Recommended starting dosage of 10 mg or 20 mg orally once daily
- Increase dosage after 4 weeks to the target dose of 20 mg once daily
- Tablets may be taken with or without food
- Different starting doses based on eGFR levels
- Monitoring serum potassium 4 weeks after initiating treatment
- Missed doses handling instructions
Interaction
- Contraindicated with strong CYP3A4 inhibitors
- Monitoring serum potassium during concomitant use with moderate or weak CYP3A4 inhibitors
- Avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- Concomitant use with strong CYP3A4 inhibitors
- Patients with adrenal insufficiency
Side Effects
- Adverse reactions including hyperkalemia, hypotension, and hyponatremia
Pregnancy & Lactation
- No available data on use in pregnancy
- Animal studies showing developmental toxicity
- No data on presence in human milk
- Potential risk to breastfed infants
Precautions & Warnings
- Risk of hyperkalemia with decreasing kidney function
- Measure serum potassium and eGFR before initiation
- Do not initiate treatment if serum potassium is > 5.0 mEq/L
- More frequent monitoring for at-risk patients
Use in Special Populations
- Safety and efficacy not established in patients below 18 years of age
- No overall differences in safety or efficacy in elderly patients
- No dose adjustment required for elderly patients
- Avoid use in patients with severe hepatic impairment
- Consider additional serum potassium monitoring in moderate hepatic impairment
Overdose Effects
- Suspected overdose may lead to hyperkalemia
- Standard treatment for hyperkalemia required
- Unlikely to be efficiently removed by hemodialysis
Therapeutic Class
- Mineralocorticoid Receptor Antagonists
Storage Conditions
- Keep below 30°C temperature
- Away from light and moisture
- Keep out of the reach of children